fda semaglutide obesity What's New in Treatment? FDA has approved a new,

Please repost and share to help a fellow pharma professional!

GLP-1

SUPPORTS GLP-1 PRODUCTION These compounds help stimulate natural GLP-1 release, leading to better appetite control and improved insulin sensitivity

More than four in five PwO have made a serious attempt at weight loss but less than half of them would have lost 5% of their body weight over three years, and 70% of those that do are expected to regain their losses.11 This illustrates that regardless of the drivers of obesity, PwO are in an established state of pathological energy homeostasis that requires intensification of treatment beyond foundational lifestyle changes, and which often requires the use of anti-obesity medications (AOMs)